Starting from these data, we decided to investigate whether ZNF224 was involved in Imatinib-mediated transcriptional repression on c-Myc oncogene, which represents a key event in Imatinib responsiveness in CML [11–13]. The gene discussed is MYC; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.